Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173773 | 0.90 | TSHR (0.47) | TDP1L3MBTL1AKR1B10AKR1B1TSHR | |
| SCHEMBL7369619 | 0.84 | TSHR (0.62) | AKR1B10AKR1B1IDO1TSHRMAOA | |
| SCHEMBL4069939 | 0.84 | TDP1 (0.64) | TDP1L3MBTL1HRH3HRH4IDO1 | |
| SCHEMBL2269133 | 0.83 | ALDH1A1 (0.58) | TDP1L3MBTL1MAOAMAOBLMNA | |
| SCHEMBL17278365 | 0.82 | ALDH1A1 (0.54) | MAOAMAOB | |
| SCHEMBL2225297 | 0.82 | ALDH1A1 (0.54) | MAOAMAOB | |
| SCHEMBL3438748 | 0.81 | TDP1 (0.60) | TDP1L3MBTL1HRH3HRH4IDO1 | |
| SCHEMBL2233399 | 0.80 | HPGD (0.58) | LMNAFFAR1RAB9A | |
| SCHEMBL947314 | 0.80 | FFAR1 (0.59) | MAOAMAOBLMNAFFAR1RAB9A | |
| SCHEMBL1839074 | 0.80 | TDP1 (0.59) | TDP1L3MBTL1AKR1B10AKR1B1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238631-B2 | Radiolabeled amino acids for diagnostic imaging | PIRAMAL IMAGING SA (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9238631-B2 | Radiolabeled amino acids for diagnostic imaging | PIRAMAL IMAGING SA (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9238631-B2 | Radiolabeled amino acids for diagnostic imaging | PIRAMAL IMAGING SA (CH) | 2016-01-19 | — | — | US | disclosed |
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | PIRAMAL IMAGING SA (CH) | 2015-01-08 | — | — | US | disclosed |
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | PIRAMAL IMAGING SA (CH) | 2015-01-08 | — | — | US | disclosed |
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | PIRAMAL IMAGING SA (CH) | 2015-01-08 | — | — | US | disclosed |
| EP-2705012-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | Piramal Imaging SA (CH) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012150220-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-11-08 | — | — | WO | disclosed |
| EP-2520556-A1 | Radiolabeled amino acids for diagnostic imaging | Bayer Pharma Aktiengesellschaft (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-2520556-A1 | Radiolabeled amino acids for diagnostic imaging | Bayer Pharma Aktiengesellschaft (DE) | 2012-11-07 | — | — | EP | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1706386-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1609798-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | SLC1A5, SLC6A19, BCAT2 | TDP1 3981/4885L3MBTL1 3249/4885AKR1B10 3429/4885 |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | TDP1 4702/4885L3MBTL1 4513/4885AKR1B10 1903/4885 |
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | TDP1 4288/4885L3MBTL1 2011/4885AKR1B10 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.